Updated analysis of the phase III PIVOTAL trial (256 patients with resectable stage III melanoma): at median 36.8 months, neoadjuvant intralesional daromun then surgery maintained improved recurrence-free and distant metastasis-free survival versus up-front surgery.
RCTn = 256
Hauschild et al. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial